NDAOPHTHALMICOINTMENT
Approved
Aug 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACHROMYCIN is a fixed-dose ophthalmic ointment combining hydrocortisone (corticosteroid) and tetracycline hydrochloride (antibiotic) for topical eye treatment. It addresses inflammatory and infectious conditions of the eye by reducing inflammation while combating bacterial pathogens. The combination formulation provides dual therapeutic benefit in a single dosage form.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on cost management and line extension rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ACHROMYCIN offers limited growth trajectory given its LOE-approaching status and minimal linked job openings. Career value lies in managing a legacy product through transition, optimizing manufacturing costs, and supporting regulatory compliance rather than driving innovation or market expansion.
Brand ManagerProduct Manager
Worked on ACHROMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.